NORWALK, Conn., Oct. 30, 2023 /PRNewswire/ -- LifeSpan Vision Ventures, an investment firm dedicated to longevity biotech, today announced an investment in NaNotics LLC. This preclinical-stage biopharmaceutical company is developing NaNots™, novel subtractive nanoparticles that treat disease by capturing and clearing pathogenic molecules from blood. NaNots™ differ from traditional drug therapies in their ability to deplete soluble targets without interacting with the membrane forms of the same target, a feat that is typically beyond the reach of conventional drugs.

The company is advancing a pipeline of NaNots targeting oncology and inflammatory markers associated with multiple diseases that present substantial unmet medical needs. Additionally, they have announced research collaborations with Mass General Cancer Clinic, situated within Mass General Hospital, and Mayo Clinic to further enhance their therapies for specific oncology targets.

Harry Robb, Analyst at LifeSpan Vision Ventures commented: "With our first investment in the nanomedicine field, we are partnering with NaNotics, a California-based biopharmaceutical company with a vision of depleting soluble targets from blood to treat a range of diseases - and potentially aging as well. The company is backed by a dedicated and highly experienced team that is committed to leading a shift in medicine from a cell-based focus to a signal-based focus. This represents an exciting opportunity to expand treatment options and we see a great potential in their transformative therapies to have a meaningful impact on patient outcomes."

Lou Hawthorne, CEO of NaNotics and the inventor of NaNots, commented, "Lifespan Vision Ventures is an ideal investor for us, for reasons that go beyond capital. They understand that aging is potentially driven by soluble factors that also drive or enable FDA-recognized diseases, and that NaNots can therefore address both. This provides a viable FDA approval path for a therapeutic platform to address aging - which the FDA does not recognize as a disease. We look forward to collaborating with Lifespan Vision Ventures to develop and market therapeutics for treating disease and extending healthspan for all people."

About NaNotics LLC
NaNotics LLC is a preclinical stage company based in Mill Valley, CA. The company is developing a pipeline of NaNots™ against a range of oncology and inflammatory targets driving multiple diseases representing significant unmet medical need.

For more information, please visit https://www.nanotics.com/
Contact: Song Schreiber, CFO: song@nanotics.com

About LifeSpan Vision Ventures
LifeSpan Vision Ventures is a forward-thinking venture capital firm specializing in investments within the aging and longevity space. Our mission is to support and accelerate the development of innovative therapies that extend healthspan, improve the quality of life for individuals as they age, and address age-related challenges. Through strategic partnerships and investments, we aim to shape a future where aging is met with vitality, resilience, and endless possibilities.

For more information about LifeSpan Vision Ventures, please visit https://www.lifespanvisionventures.com/.

Contact: Harry Robb
mob: +44 7795042764
harry.robb@lifespanvision.com

Photo - https://mma.prnewswire.com/media/2259807/LifeSpan_Vision_Ventures_Invests_in_NaNotics.jpg

View original content:https://www.prnewswire.co.uk/news-releases/lifespan-vision-ventures-invests-in-nanotics-301971753.html

Images

Tags

More Like This

LifeSpan Vision Ventures Makes 7th Investment in Pursuit of Longevity Mission

Lifespan Vision Ventures invests in Bolden Therapeutics

LifeSpan Vision Ventures Invests in Matter Bio

LifeArc Ventures 2024: new investments, targeted follow-ons and substantive portfolio progress

LifeArc Ventures - six new investments, portfolio progress and an expanding investment team

NanoViricides Announces that Clinical Trials of Its Broad-Spectrum Antiviral Drug NV-CoV-2 Have Begun

Nanoscope Therapeutics Announces Positive Top-line Results from Randomized Controlled Trial of MCO-010 for Retinitis Pigmentosa

Vector Laboratories and Navinci Diagnostics Announce Strategic Collaboration to Develop Novel Spatial Proteomic Tools Enabling Biomarker Discovery